drugset / Trial / NCT02652052

Hematopoietic Stem Cell Transplant Survivors Study

NCT02652052

Phase 1 Completed 9 enrolled Mayo Clinic
RandomizedParallel-groupOpen-labelSupportive care

Summary

The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis.

Timeline

Start
2016-03-01
Primary completion
2023-05-23
Completion
2023-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Quercetin Small molecule 1000 mg Oral
Subject dasatinib anhydrous Small molecule 100 mg Oral